Summary
Hedge funds are significantly increasing their investments in US healthcare stocks, reaching near a five-year high, according to Goldman Sachs. This trend is driven by the integration of artificial intelligence in drug discovery and expedited approval processes by the Food and Drug Administration, boosting investor confidence in the sector.